Participated · Series A · Jul 2026

Luffy AI builds a neuroplastic AI platform that uses sparse neural networks trained in simulation and refined during real-world operation to enable real-time adaptive control without relying on large datasets or continuous cloud retraining. The technology is initially deployed in industrial motor control and integrated with variable frequency drive (VFD) systems such as pumps, fans and conveyor systems. Luffy’s approach aims to improve energy efficiency, reduce commissioning time and optimise performance in physical systems. The company plans to expand into additional applications including robotics, drones and thermal process control. Luffy is commercialising its solutions through proof-of-concept projects and pilot deployments with industrial customers and will use new funding to convert those into long-term partnerships and scale rollout. Dr Matthew Carr is a co-founder and CEO and has framed the funding as enabling increased delivery and deployment efforts.

Participated · Equity · Apr 2026

TIBEAY Biosciences is a clinical-stage biotechnology company based in the Netherlands focused on developing innovative therapies for acute neurological diseases. Its lead candidate, Ronopterin, is described as a first-in-class inhibitor of inducible nitric oxide synthase (iNOS) intended to reduce secondary brain damage after severe traumatic brain injury (SHT). The company plans a European multicenter Phase 3b study and aims to submit a marketing authorization application to the EMA based on that trial. The recently completed €35 million financing will fund the Phase 3b study, production of the investigational product, supply-chain activities, and regulatory and operational preparations for potential approval. TIBEAY is engaging investors including Münchner Athos KG, MIG Fonds, Meneldor and Oost NL to support its clinical and regulatory programs. The company positions Ronopterin as targeting an unmet medical need where no approved pharmacologic therapies currently exist.

Participated · Equity · Jan 2026

GlassPoint builds, owns, and operates enclosed-trough solar facilities that generate high-temperature steam for industrial customers, claiming to supply 60% of the world’s installed solar industrial steam capacity. Its core Enclosed Trough collectors convert nearly 70% of incoming sunlight into heat, while the Unify Storage System stores that heat for night-time use, giving customers round-the-clock thermal energy. Flagship deployments include a 1.5 GWth project with Ma'aden to decarbonize a Saudi bauxite refinery, a 750 MWth system that will help Searles Valley Minerals retire California coal plants, and a 330 MWth plant that has delivered daily steam in Oman since 2017. The company is now targeting new megaprojects across the U.S. Southwest, Southern Europe, the Middle East, and South America. Proceeds from its latest funding will also expand its Stuttgart Technology Center and grow business development, engineering, and finance teams in Dubai and the United States. GlassPoint positions its solution as a cheaper alternative to burning fossil fuels or electrification for process heat, aiming to lower both emissions and operating costs for heavy industry.

Led · Seed · Nov 2025

Founded in 2023, NcodiN is a Paris-based deep-tech startup building NConnect, a photonic interposer platform that embeds record-small, energy-efficient nanolasers directly onto silicon chips. The technology replaces traditional copper links, delivering sub-0.1 pJ/bit optical connections that unlock the high memory bandwidth and scalability required for AI superchips. Over the past 18 months the company has demonstrated full optical links, integrated nanodetectors, and established its own cleanroom to accelerate joint prototyping with partners. With its seed financing, NcodiN plans to move from R&D to industrial scale by running a CMOS pilot line on 300 mm wafers, building out its supply chain, and expanding key engineering hires. The company will also open a Silicon Valley office to deepen customer relationships and prepare for large-scale manufacturing partnerships. NcodiN positions itself as the optical backbone of “more-than-Moore” computing, aiming to enable wafer-scale supercomputers within a single processor package.

Participated · Equity · Sep 2025

AMSilk develops advanced biomaterials from silk-based proteins using a patented technology platform and a supporting patent portfolio. It converts man-made proteins into formulations including fibers and yarns, hydrogels, and silk powder. The company’s high-performance materials target applications across the textile, homecare, biomedical, and automobile industries. AMSilk has collaborated with global companies and intends to continue partnering with enterprises worldwide. The company plans to use the new funds to build further commercial traction and to support the next phase of industrial scale-up to meet growing global demand. The raise followed an extension of its Series C financing in 2023. AMSilk produces bio-fabricated silk protein materials using a patented biotechnological process, converting plant-based renewable inputs into powders, hydrogels, fibers, and coatings. Its materials are 100% protein, do not involve natural farming processes, and are fully biodegradable under aerobic and marine conditions without generating microplastics. The company plans to use the new funding to accelerate industrial scale-up and expand commercial operations for its biotech materials. AMSilk raised an additional €25M in a Series C extension, bringing the total Series C to €54M. The extension was led by ATHOS (AT Newtec) with participation from Novo Holdings, Cargill, and MIG Capital. Since a €29M financing in 2021, AMSilk has invested in partnership agreements and supply contracts with leading apparel, medical, automotive, and biotech companies. AMSilk is an industrial supplier of synthetic silk biopolymers based in Planegg, near Munich, Germany. Its products are produced from plant-based raw material via bacterial fermentation and possess mechanical and biochemical properties suitable for multiple industries. The company offers high-performance Biosteel® fibers for textiles and industrial applications worldwide and cites use cases in medical devices and personal care products. AMSilk has announced collaborations and partnerships with brands like Adidas and Airbus. Led by CEO Ulrich Scherbel, the company plans to accelerate scale-up of its industrial projects and internationalize commercial activities to expand its customer base into new markets. It raised €29M in a Series C round to fund these efforts. AMSilk produces and processes SPIDERSILK biopolymers copied from the proteins of web-weaving spiders. These biopolymers enable new technical products and improvements to existing products. According to the company, the materials offer mechanical toughness, chemical resistance and biocompatibility while being completely biodegradable. AMSilk completed a €5m Series B financing and intends to use the capital to expand development and sales efforts for its first spider silk-based products. The company plans to pursue those efforts through partnerships with leading companies across major industries. Founded in 2008 as a spin-off from the Technische Universität München, AMSilk is led by Managing Director Axel Leimer.